Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
ACS Infectious Diseases|August 2, 2016
Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis RegimenNoton K Dutta, Rongjun He, Michael L Pinn, et al.Current Alzheimer Research|June 25, 2005
Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitorsChad A Dickey, Jason Eriksen, Adeela Kamal, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 17, 2014
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancerBarbara J Gitlitz, Eric Bernstein, Edgardo S Santos, et al.Clinical Pharmacology and Therapeutics|March 19, 2026
Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib CombinationJaehee Shim, Douglas Chung, Alison Smith, et al.Oncotarget|April 20, 2016
Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cellsMonica Pallis, Francis Burrows, Jeremy Ryan, et al.International Journal of Cancer|December 31, 2005
The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?Catherine R Barker, Jane Hamlett, Stephen R Pennington, et al.Molecular Cancer Therapeutics|March 25, 2026
Farnesyl transferase inhibitor KO-2806 (darlifarnib) enhances the anti-tumor activity of tyrosine kinase inhibitors in RCCJovylyn G Gasendo, Stacia Chan, Hetika V Patel, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 9, 2006
HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sitesChad A Dickey, Judith Dunmore, Bingwei Lu, et al.Molecular Cancer Therapeutics|May 30, 2006
Identification of new biomarkers for clinical trials of Hsp90 inhibitorsHong Zhang, Daun Chung, Yong-Ching Yang, et al.International Journal of Cancer|November 30, 2006
Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activityHong Zhang, Yong-Ching Yang, Lin Zhang, et al.Pageof 4